COVID-19 and Inflammatory Diseases

You might wonder, “Is there a link between the coronavirus and the challenges of chronic inflammation?” Both conditions, though distinct, center around infection. COVID-19 arises from the SARS-CoV-2 virus, while chronic inflammation is believed to be influenced by certain infections. Given this connection, we are eager to highlight the insights ACC offers in addressing various infections, including the pervasive coronavirus.

Exploring the Potential Link Between COVID-19 and Inflammatory Diseases: Success of AMOR18 Clinical Trial for Corona Patients.
AMOR18, a significant component also found in PH Gastrilex, has shown promising results in clinical trials for treating COVID-19 patients. This key ingredient, shared by both AMOR18 and Gastrilex, represents a notable breakthrough in addressing both the coronavirus and inflammatory diseases.

The outbreak of COVID-19 has not only posed significant challenges to public health but has also shed light on the connection between the virus and inflammatory diseases. COVID-19, caused by the SARS-CoV-2 virus, has been associated with various inflammatory conditions, such as pneumonia and acute respiratory distress syndrome (ARDS). Understanding and addressing the inflammatory response triggered by the virus is crucial in developing effective treatments. In this context, Dr. Nashat Abu Salah, Director of the Corona Department and Director of the Geriatrics Department at Ziv Medical Center in Safed, shares insights on the success of the clinical trial for a potential cure for corona patients.

The trial utilized the new drug AMOR18, developed in Israel in collaboration with the inflammation global care, which showed promising results in treating COVID-19 patients. Administered through inhalation and as a powder under the tongue, this unique medication containing amorphous calcium carbonate as the active substance has demonstrated a remarkable 100% success rate, leading to swift recovery and subsequent discharge of patients. These encouraging outcomes bring hope not only to the corona patients in Israel but also to the broader field of medicine worldwide.



Dr. Nashat also explained phase 2 of the clinical trial: In the double-blind trial, 50% of the patients received the new drug AMOR-18 and the remaining 50% received a placebo (dummy drug). A total of 37 patients in a moderate-severe condition participated. Of these, 18 patients were treated with the new drug AMOR-18, recovered, and were discharged home within a few days. The other 19 patients were treated with a placebo, of whom 6 were transferred to the Intensive Care Unit and 2 unfortunately succumbed to the disease.

So far, 58 patients have volunteered for the trial, and these days the clinical trial continues in medical centers such as Ziv, Shamir, Kaplan, and Ma’eini Hashuah. The research is expected to expand in the coming weeks to a hospital in Brazil, where the experiment will be conducted on COVID-19 infected individuals.

The drug, given by inhalation and as a powder under the tongue, raises the pH level in the body, halting the deterioration process in severe COVID-19 patients and activating the immune system until recovery. Amorphical’s amorphous calcium carbonate stands as the unique development in this medicine.

A zoom in image of Amorphous Calcium Carbonate
(ACC) with its unique, and non-crystalline form

A zoom in image of Amorphous Calcium Carbonate
(ACC) with its unique, and non-crystalline form

Our recommendation for first time users:

If you are a new customer, your satisfaction and positive results are our top priority.

This is why we recommend starting with three packages for your initial trial. Typically, you can expect to notice improvements within 3 to 4 weeks of regular use.

Should the product not meet your expectations or fail to deliver results, we offer a money-back guarantee on each unopened package